DTIL PRECISION BIOSCIENCES INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$7.62

Period return

+3.37 (+79.29%)

Volume

348.2K

2026-07-21O $7.36 H $7.68 L $7.31 C $7.62MA5 $8MA20 $8.07MA60 $7.39MA120 $6.38

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 28.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2025. 05. 21.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2025. 03. 28.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 03. 20.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 02. 20.LowBUYlast year
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 01. 10.LowBUY2 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $32 · 4 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Sector: Healthcare
Industry: Biotechnology
HQ: Durham, NC, United States
Fiscal year end: —

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$-0.6	—	—	$1.75M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-2.21	—	—	$29K	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$3.78	—	—	$68.06M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$6.81	—	—	$67.48M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	307,790	$1.69M	0.00%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	139,531	$580.45K	0.00%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	35,593	$195.76K	0.00%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	29,607	$123.17K	0.00%	—	New position

PRECISION BIOSCIENCES INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 28.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 05. 21.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 03. 28.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 03. 20.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 02. 20.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 01. 10.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy